drugset / Trial / NCT00852566

Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia

NCT00852566

Phase 2 Completed 46 enrolled Norwegian University of Science and Technology
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized multi-center study comparing the effect of dasatinib and imatinib on malignant stem cells in newly diagnosed chronic phase chronic myeloid leukemia (CML) patients. The research hypothesis is that treatment with dasatinib 100 mg daily (QD) results in greater and more rapid depletion of the Philadelphia (Ph) -positive stem cell pool within 6 months of therapy than imatinib 400 mg QD in newly diagnosed CML patients. The study duration is 18 months and approximately 40 patients will be recruited to the study.

Timeline

Start
2009-03
Primary completion
2011-02
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Imatinib Small molecule 400 mg Oral
Subject dasatinib anhydrous Small molecule 100 mg Oral